Bromfenac - Bausch & Lomb/Senju Pharmaceutical
Alternative Names: AHR 10282B; Bromday; Bronuck; Duract; Natax; Nuckone; Prolensa; Remura; WAY-PEM 420; Xibrom; XiDay; YelloxLatest Information Update: 25 Sep 2021
At a glance
- Originator Wyeth
- Developer Bausch & Lomb; Croma Pharma; ISTA Pharmaceuticals; Senju Pharmaceutical
- Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ocular inflammation; Ocular pain
- Market Withdrawal Postoperative pain
- No development reported Age-related macular degeneration
- Discontinued Dry eyes; Dysmenorrhoea; Osteoarthritis
Most Recent Events
- 01 Jul 2019 Bromfenac is not yet available for Ocular inflammation in Malaysia (Ophthalmic)
- 15 Jun 2017 Bausch & Lomb completes a phase III trial in Ocular pain (In adults, In the elderly) in Spain (Ophthalmic) (EudraCT2015-002155-10)
- 21 Feb 2017 Senju Pharmaceutical plans a phase I trial for Diabetic macular oedema in Japan (UMIN000026201)